Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Glykos-M Gliclazide and Metformine Hydrochloride Sustained-Release Tablet:
Introducing Glykos-M, a sustained-release tablet combining Gliclazide and Metformin Hydrochloride, specifically formulated to provide effective and long-lasting management of Type 2 diabetes mellitus. This combination offers a dual mechanism to control blood sugar levels efficiently.
Uses of Glykos-M Gliclazide and Metformine Hydrochloride Sustained-Release Tablet:
Glykos-M Tablets are used for:
Managing Type 2 diabetes mellitus
Improving glycemic control in diabetic patients
Reducing blood sugar levels and enhancing insulin sensitivity
Lowering glucose production in the liver
Benefits of Glykos-M Gliclazide and Metformine Hydrochloride Sustained-Release Tablet:
Combines Gliclazide and Metformin for comprehensive diabetes management
Sustained-release formulation ensures prolonged action and better control
Helps in achieving and maintaining target blood sugar levels
Reduces the risk of diabetes-related complications
Mechanism of Action of Glykos-M Gliclazide and Metformine Hydrochloride Sustained-Release Tablet:
Gliclazide: A sulfonylurea that stimulates the release of insulin from pancreatic beta cells, helping to lower blood sugar levels. It also improves the bodys insulin sensitivity.
Metformin Hydrochloride: A biguanide that decreases hepatic glucose production, reduces intestinal absorption of glucose, and enhances insulin sensitivity by increasing peripheral glucose uptake and utilization.